P

uzzled by those controversial Alzheimer’s disease data from Biogen and Eisai? We asked an expert to break down what they mean for patients, for science, and for the future of what could be a promising treatment for a devastating disease.

Dr. Howard Fillit, chief science officer of the Alzheimer’s Drug Discovery Foundation, joined us to answer STAT Plus subscribers’ questions on BAN2401, the therapy from Biogen and Eisai that just completed Phase 2 testing.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Dear Howard, we did show amyloid plaque removed from the brain 10 years ago with the 1st study with bapineuzumab using C-11 PIB. It very effectively removed amyloid from the brain. Maybe it was space technology then, but it’s true

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy